Advaxis' IPO

Advaxis raised a round of funding on December 13, 1999. Investors include Public.

Advaxis, Inc. is a biotechnology company that uses a bioengineered bacterium, Listeria monocytogenes to activate the immune system to treat cancer, infectious disease or allergic syndromes.…

Articles about Advaxis' IPO: